Drugs / Autologous mesenchymal stem cells
Autologous mesenchymal stem cells
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03477942 | Oct 2018 → Jul 2026 overdue | articular cartilage disorder, osteoarthritis, knee | University Hospitals Cleveland Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02460770 | Jun 2015 → Jun 2017 | myocardial ischemia | University Hospital, Toulouse | Withdrawn | No outcome recorded |
| Phase 1 | NCT02945462 | Sep 2013 → Nov 2015 | erectile dysfunction | University of Jordan | Completed | No outcome recorded |
| Phase 1 | NCT03778333 | Dec 2012 → Dec 2016 | multiple sclerosis | Karolinska Institutet | Completed | No outcome recorded |
| Phase 1 | NCT01758055 | Dec 2012 → Dec 2013 | pulmonary emphysema | Arda Kiani | Unknown | No outcome recorded |
| Phase 1 | NCT01609283 | May 2012 → Jan 2019 | amyotrophic lateral sclerosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06858254 | Apr 2025 → Apr 2028 expected | Parkinson disease | Apeiron Research Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04432467 | Oct 2020 → Sep 2021 | adhesions of uterus, chronic endometritis, fallopian tube disorder | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Completed | No outcome recorded |
| Phase 1/2 | NCT02315027 | Oct 2012 → Mar 2027 expected | mitochondrial import-stimulating factor | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01895439 | Oct 2012 → Feb 2016 | multiple sclerosis | University of Jordan | Completed | No outcome recorded |
| Phase 1/2 | NCT02062931 | Mar 2012 → May 2015 | primary ovarian failure | Sayed Bakry | Unknown | No outcome recorded |
| Phase 1/2 | NCT02497443 | Apr 2011 → Dec 2017 | epilepsy | Ministry of Public Health, Republic of Belarus | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02064062 | Jan 2015 → Dec 2018 | tendinitis, tendinosis | University College, London | Unknown | No outcome recorded |
| Phase 2 | NCT02249676 | Jan 2013 → Dec 2014 | neuromyelitis optica | Tianjin Medical University General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00875654 | Aug 2010 → Oct 2017 | ischemic disease, stroke disorder | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 2 | NCT00911365 | May 2008 → Jun 2011 | multiple system atrophy | Yonsei University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04146519 | Jul 2017 → Dec 2021 | — | Belarusian Medical Academy of Post-Graduate Education | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02755922 | Apr → Sep 2010 | — | Mexican Social Security Institute | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT02981576 Comparator | Nov 2016 → May 2018 | spinal cord injury | University of Jordan | Completed | No outcome recorded |
| Phase 2 | NCT05167721 Comparator | Dec 2021 → Dec 2026 expected | multiple system atrophy | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02118519 Comparator | Jan 2014 → Aug 2015 | articular cartilage disorder, osteoarthritis, knee | University of Jordan | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous mesenchymal stem cells | “Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure” NCT02062931 ↗20“Autologous mesenchymal stem cells derived bone marrow, bronchoscopy” NCT01758055 ↗ |
| Known as | adipose-derived autologous MSCs | “adipose-derived autologous MSCs were delivered intrathecally to patients with early MSA utilizing a dose-escalation design” NCT05167721 ↗ |
| Known as | autologous bone marrow mesenchymal stem cells | “intranasal and intravenous autologous bone marrow mesenchymal stem cells (BM-MSCs) for Parkinson Disease (PD) and Parkinson's Plus (PPS) patients” NCT06858254 ↗ |
| Known as | autologous bone marrow-derived mesenchymal stem cells | “2 consecutive intracavernous (IC) injection of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) for the first time in the treatment of diabetic patients with...” PMID 38965462 ↗ Jul 2024 |
| Known as | BM-MSCs | “2 consecutive intracavernous (IC) injection of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) for the first time in the treatment of diabetic patients with...” PMID 38965462 ↗ Jul 20242“This study aimed at testing the safety of autologous bone marrow mesenchymal stem cells (BM-MSCs) expanded in vitro when given intra-articularly to patients with stage II and III KOA.” PMID 29233163 ↗ Dec 2017 “intranasal and intravenous autologous bone marrow mesenchymal stem cells (BM-MSCs) for Parkinson Disease (PD) and Parkinson's Plus (PPS) patients” NCT06858254 ↗ |
| Known as | bone marrow-derived mesenchymal stem cells | “2 consecutive intracavernous (IC) injection of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) for the first time in the treatment of diabetic patients with...” PMID 38965462 ↗ Jul 2024 |
| Known as | mesenchymal stem cells | “25 million mesenchymal stem cells administered intrathecally every 3 months for 4 injections” NCT05167721 ↗ |
| Known as | MSC | “This study focuses on the effects of autologous mesenchymal stem cells (MSC) in drug-resistant epilepsy patients within a Phase I/II open-label registered clinical trial NCT02497443.” PMID 34119901 ↗ Jun 2021 |
| Known as | MSCs | “The pts in the study group received one slowly delivered (over 5-10 minutes) intravenous injection of ex vivo expanded autologous MSCs in a volume of 20 ml” NCT02497443 ↗2“adipose-derived autologous MSCs were delivered intrathecally to patients with early MSA utilizing a dose-escalation design” NCT05167721 ↗ “there does not appear to be any studies of the use of autologous cultured mesenchymal stem cells (MSCs) for AT.” PMID 29764889 ↗ May 2018 |
| Action | Restore | “This "restorative" therapy aims to replace destroyed cerebral tissue with a stem cells graft.” NCT00875654 ↗ |
| Modality | Cell therapy | “Our research project involves a development of cell therapy in a phase IIa clinical trial of feasibility and safety in patients (randomised, controlled, open, with 3 parallel groups).” NCT00875654 ↗ |
| Route | Intravenous | “In this RCT, we assessed the safety, feasibility, and efficacy of intravenous autologous bone marrow-derived MSCs in subacute stroke.” PMID 32462427 ↗ May 2020 |